Soligenix $SNGX HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding

Soligenix recently announced an exciting update for its novel skin cancer treatment. The company reports that its flagship product candidate, HyBryte™, is showing impressive results in treating a rare form of skin cancer called cutaneous T-cell lymphoma or CTCL, with 75% of patients seeing significant improvement after just 18 weeks.